Aim: 20(S)-Ginsenoside Rh2 (Rh2) has shown potent inhibition on P-glycoprotein (P-gp), while most HIV protease inhibitors are both substrates and inhibitors of P-gp and CYP3A4. The aim of this study was to investigate the potential pharmacokinetic interactions between Rh2 and the HIV protease inhibitor ritonavir. Methods: The effects of Rh2 on the cellular accumulation and transepithelial transport of ritonavir were studied in Caco-2 and MDCK-MDR1 cells. Male rats were administered Rh2 (25 or 60 mg/kg, po) or Rh2 (5 mg/kg, iv), followed by ritonavir (25 mg/kg, po). The P-gp inhibitors verapamil (20 mg/kg, po) or GF120918 (5 mg/kg, po) were used as positive controls. The concentrations of ritonavir in plasma, bile, urine, feces and tissue homogenates were analyzed using LC-MS. Results: Rh2 (10 μmol/L) significantly increased the accumulation and inhibited the efflux of ritonavir in Caco-2 and MDCK-MDR1 cells, as verapamil did. But Rh2 did not significantly alter ritonavir accumulation or transport in MDCK-WT cells. Intravenous Rh2 significantly increased the plasma exposure of ritonavir while reducing its excretion in the bile, and oral verapamil or GF120918 also increased plasma exposure of ritonavir but without changing its excretion in the bile. Interestingly, oral Rh2 at both doses did not significantly change the plasma profile of ritonavir. Moreover, oral Rh2 (25 mg/kg) significantly elevated the ritonavir concentration in the hepatic portal vein, and markedly increased its urinary excretion and tissue distribution, which might counteract the elevated absorption of ritonavir. Conclusion: Rh2 inhibits the efflux of ritonavir through P-gp in vitro. The effects of Rh2 on ritonavir exposure in vivo depend on the administration route of Rh2: intravenous, but not oral, administration of Rh2 significantly increased the plasma exposure of ritonavir.
Introduction
HIV protease inhibitors (PIs) are commonly used as part of highly active anti-retroviral therapy (HAART) for HIV infection to control virus replication and disease progression [1] . Despite the clinic significance of PIs, accumulating clinical evidence indicates that the incorporation of HIV PIs into HAART is associated with various adverse effects, such as metabolic syndrome characterized by dyslipidemia, insulin resistance, and lipodystrophy [2, 3] . 20(S)-Ginsenoside Rh2 (Rh2), a component isolated from red ginseng [4] , is one of the most studied ginsenosides due to its various pharmacological activities, such as anti-cancer effects, anti-hyperglycemic effects, and anti-obesity effects [5] [6] [7] [8] . Rh2 has been approved as a complementary food by the China State Food and Drug Administration since 2006, and it can be speculated that Rh2 is popular among HIV-infected patients, especially in the individuals with AIDS and cancer.
Most PIs are both substrates and inhibitors of P-glycoprotein (P-gp) [9, 10] and CYP3A4 [11, 12] . Recently, it was found that Rh2 is # These authors contribute equally to this article. * To whom correspondence should be addressed.
a potent noncompetitive inhibitor of P-gp [13] [14] [15] , indicating that there may be a potential pharmacokinetic interaction between Rh2 and the P-gp substrate of PIs. Ritonavir (RTV), one of the most commonly used HIV PIs, has been demonstrated to be a substrate and inhibitor of P-gp both in vitro and in vivo [9, 10, 16, 17] . However, few studies have focused on the interactions between ginsenosides and antiretrovirals [18, 19] . To our knowledge, the pharmacokinetic interactions between HIV PIs and Rh2 remain unknown. Thus, the goal of this study was to evaluate the potential pharmacokinetic interactions between a typical PI agent -RTV -and Rh2 using both in vitro and in vivo models.
Materials and methods
Chemicals and reagents Rh2 (purity >98%) was purchased from Jilin University (Changchun, China). RTV was kindly donated by Dr Huiping ZHOU (Virginia Commonwealth University, Richmond, VA, USA). Verapamil (Ver) and digitoxin were purchased from the Chinese National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). GF120918 was purchased from J&K Scientific Ltd (Shanghai, China). Acetonitrile was purchased from Merck Co (Darmstadt, Germany). Deionized water was prepared using a Milli-Q system (Millipore, Milford, MA, USA). Ethylacetate and all other reagents and solvents were purchased from commercial sources and were of analytical grade.
Cell culture
Caco-2 cells were purchased from the American Type Culture Collection (Rockville, MD, USA). Wild-type MDCK cells (MDCK-WT) and MDCK cells transfected with the human MDR1 gene (MDCK-MDR1) were obtained from Zhejiang University (Hangzhou, China). All of the cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 110 mg/L pyruvic acid sodium, 3.7 mg/L HEPES, 62.5 mg/L penicillin, and 100 mg/L streptomycin (Invitrogen) and incubated at 37 °C in an atmosphere of 5% carbon dioxide and 90% relative humidity. The cell culture medium was refreshed every 2 d until the cells reached confluence. All of the cells were used between passages 30 and 45 and tested negative for mycoplasma infection.
Cellular accumulation study
The accumulation studies were performed with confluent epithelial monolayers of Caco-2, MDCK-WT, and MDCK-MDR1 cells. The cells were pre-treated with Hanks' balanced salt solution (HBSS, pH 7.4) containing Rh2 or 0.1% dimethyl sulfoxide (DMSO, control) at 37 °C for 0.5 h, followed by the addition of RTV for specified time. After the retention period had passed, the drugs were withdrawn, and the cells were rinsed with ice-cold HBSS. Ver was used as a positive control P-gp inhibitor. The cells were lysed by three freeze-thaw cycles, and the protein concentrations were measured using a Bradford protein assay kit (BioRad, Hercules, CA, USA) according to the manufacturer's instructions. The RTV concentrations were determined by liquid chromatography-mass spectrometry (LC-MS) and were expressed as ng/mg protein.
All experiments were conducted in triplicate. All of the drugs (RTV, Rh2, and Ver) were prepared by dissolution in DMSO and dilution with HBSS. The final concentration of DMSO was no more than 0.2% (v/v).
Transepithelial transport studies
For the transport experiments, cells at a density of 1.5×10 5 cells/insert were seeded on a permeable polycarbonate insert (Millicell cell culture inserts, 0.4 μm pore size, 12 mm diameter, Millipore, USA) in 24-well culture plates and were used for the experiment at 18-21 d (Caco-2 cells) or 5-6 d (MDCK-WT and MDCK-MDR1 cells) after seeding. TEER measurements (Millicell-ERS Epithelial Voltohmmeter, Millipore Co, Milford, MA, USA) were used to evaluate the integrity of the cell monolayers. The monolayers used in the transport studies had TEER values exceeding 500 Ω·cm 2 for the Caco-2 and MDCK-MDR1 cells and 180 Ω·cm 2 for the MDCK-WT cells. On the day of experiment, the cell monolayers were pretreated with HBSS containing Rh2 (1, 5, and 10 μmol/L) or 1‰ DMSO (control) at 37 °C for 0.5 h. Then, 2 μmol/L RTV was added to either the apical (AP) or basolateral (BL) side to evaluate transport in the absorptive and secretory directions, respectively. The cell monolayers were incubated for another 1 h. Ver was used as the positive control. At the end-point, samples were taken from the receiving chamber for analysis by LC-MS. All experiments were conducted in triplicate.
Animals
Healthy male Wistar rats (180-220 g) were obtained from the Experimental Animal Breeding Center of Yangzhou University (Yangzhou, China) and housed under environmentally controlled conditions with a 12-h light-dark cycle. The animals were acclimated to the environment for 5 d before the experiment. Prior to each experiment, the rats were fasted overnight (12 h) with free access to water. The animals were randomly assigned to different experimental groups. The animal experiments were carried out in accordance with the Guidelines for Animal Experimentation of China Pharmaceutical University (Nanjing, China), and the protocol was approved by the Animal Ethics Committee of this University.
Pharmacokinetic studies in rats
To evaluate the effect of Rh2 on the pharmacokinetics of RTV, the rats were divided into seven groups. Two groups of rats were intragastrically administered a single dose of Rh2 at 25 mg/kg or 60 mg/kg suspended in 0.5% CMC-Na. One group of rats was injected with a single dose of Rh2 (5 mg/kg) via the caudal vein. Two groups received the typical inhibitors of P-gp, Ver (20 mg/kg, po) and GF120918 (5 mg/kg, po). The two blank control groups received either the intragastric vehicle (0.5% CMC-Na) or the intravenous vehicle (20% ethanol+30% propylene glycol+50% dextrose, 5%). Thirty minutes (the two intravenous groups) or one hour (all other groups) Collection of rat bile, urine, feces, and hepatic portal vein plasma The rats were randomly classified into four groups, ie, the vehicle control (0.5% CMC-Na, po) group, the Rh2 (25 mg/kg, po) group, the Rh2 (5 mg/kg, iv) group, and the GF120918 (5 mg/kg, po) group. For the collection of rat bile, cannulas were surgically inserted into the bile duct after anaesthetization with diethyl ether. Thirty minutes (the iv group) or one hour (all other groups) later, RTV (25 mg/kg) in 0.5% CMC-Na was administered orally to the rats. Bile samples were collected -2 to 0 h before drug administration and 0-2, 2-4, 4-6, 6-8, and 8-12 h after drug administration. A solution of 100 mmol/L taurocholic acid salt in 0.9% saline-0.5% KCl was infused at 0.5 mL/h into the duodenum. Samples were stored at -20 °C until analysis.
For the collection of urine and feces, the four groups of rats (mentioned above) were housed in individual metabolic cages. Urine was collected and the volume was measured between -12 and 0 h before drug administration and during the periods of 0-6, 6-12, 12-24, 24-36, and 36-48 h after drug administration. Feces were collected for the periods -12 to 0 h before drug administration and 0-12, 12-24, 24-36, 36-48, and 48-72 h after drug administration. The samples were weighed and mechanically homogenized in water (1:5, w/w) for 5 min and stored at -20 °C until analysis.
For the collection of rat hepatic portal vein plasma, heparinized cannulas were surgically inserted into the vicinity of the junction of the gastroduodenal vein after anaesthetization. Thirty minutes (the iv group) or one hour (all other groups) later, RTV (25 mg/kg) in 0.5% CMC-Na was administered orally to the rats. Blood samples were collected at 0, 0.5, 1, 2, 4, 6, and 8 h in heparinized tubes. Plasma was obtained by centrifugation at 5000×g for 10 min and stored at -20 °C until analysis.
Rat tissue distribution
The rats were intragastrically administered a single dose of Rh2 (25 mg/kg) or vehicle (0.5% CMC-Na) one hour before the oral administration of RTV (25 mg/kg, po). At 3 and 6 h after RTV administration, the male Wistar rats (four at each time point) were sacrificed immediately after blood sampling. The primary tissues (heart, liver, spleen, lungs, kidneys, brain, stomach, small intestine, fat, and testes) were harvested, weighed, and homogenized with 0.8% NaCl saline containing 0.01 mol/L Tris-HCl, 0.001 mol/L Na 2 EDTA, and 0.01 mol/L saccharose (pH 7.4). The supernatants of the tissue homogenates obtained after centrifugation were stored at -80 °C until analysis.
LC-MS analysis
Samples of the cell lysates, rat plasma, urine, feces, and bile spiked with 10 μL of internal standard solution (10 μmol/L digitoxin) were extracted with ethyl acetate. After centrifugation, the upper organic phase was evaporated to dryness (Thermo Savant SPD 2010 SpeedVac System, Thermo Electron Corporation, USA). The residue was reconstituted in 100 μL of acetonitrile, followed by another centrifugation. Five microliters of supernatant was injected into the LC-MS system and separated with an Inertsil ODS-3 column (150 mm×2.1 mm id, 5 μm, GL Science Inc, Japan) fitted with a C18 guard column (4.6 mm×12.5 mm, 5 μm, Agilent, USA) at 40 °C. A Shimadzu 2010A LC-MS system (Shimadzu, Kyoto, Japan) with an ESI source was used to perform the analysis. Data acquisition was performed with LCMSsolution Version 2.04 (Shimadzu Corp, Japan). The mobile phase consisted of solvent A (0.002% ammonium chloride in water) and solvent B (acetonitrile) using the following gradient: 40%-60% B (linear, 0.03 min), 60%-80% B (B Curve Value=-3, 4.97 min), 80%-88% B (linear, 0.03 min), 88% B (1.97 min), 88%-40% B (linear, 0.5 min), and 40% B (4.5 min) for equilibration. The flow rate was set at 0.2 mL/min. In SIM mode, the negative ions of RTV, Rh2, and digitoxin (internal standard) were monitored at m/z 755. 
Data analysis
The apparent permeability (P app ) of RTV across the cell monolayers used for transport studies was calculated with the following formula:
, where C 0 is the concentration of the test drug in the donor chamber, S is the surface area of the monolayer, and ΔQ/Δt is the permeability rate (nmol/s). The efflux ratio (ER), which is the ratio of BL-to-AP transport to AP-to-BL transport, was calculated using the following equation: ER=P app (BL-AP)/P app (AP-BL), where P app (BL-AP) and P app (AP-BL) represent the apparent permeability of the test compound in the BL-to-AP direction and the AP-to-BL direction of the cellular monolayer, respectively.
The pharmacokinetic parameters of RTV were obtained by noncompartmental analysis using WinNonLin Phoenix version 6.3 (Pharsight Corp, Mountain View, CA, USA). The area under the plasma concentration-time curve (AUC) was calculated using the trapezoidal method. The terminal half-life (t 1/2 ) was calculated as ln2/k, where k, the elimination rate constant, was determined from the slope of the terminal regression line. Absolute bioavailability (F) was determined by the equation (AUC po ×Dose iv )/(AUC iv ×Dose po ).
In the excretion studies, the cumulative excretion rate was calculated by the following equation: (cumulative excretion/ total amount)×100%.
Statistical analysis
The data are presented as the mean±SEM. Comparisons between groups were performed using Student's t-test. For multiple comparisons, a one-way analysis of variance followed by Dunnett's test was applied. A probability value of <0.05 was considered significant. Figure 1B ). The classic P-gp inhibitor Ver (100 μmol/L) exhibited a potent inhibitory effect on P-gp, resulting in a significant 2.78-fold increase in the intracellular accumulation of RTV (P<0.01).
In addition, the effect of Rh2 on RTV transport across Caco-2 monolayers was examined. As shown in Figure 1C , the P app values of RTV in the BL-to-AP direction were markedly higher than those in the AP-to-BL direction, with an efflux ratio (BLto-AP/AP-to-BL) of approximately 5.51. In the presence of 1, 5, and 10 μmol/L Rh2, the efflux ratio of RTV gradually decreased from 3.82 to 1.82 and finally 1.44. Ver (100 μmol/L) decreased the efflux ratio of RTV to 1.24. Figure  2C ). The established P-gp inhibitor Ver (100 μmol/L) exhibited a potent inhibitory effect on P-gp, resulting in a significant 3.40-fold increase in the intracellular accumulation of RTV (P<0.01). However, neither Rh2 nor Ver exhibited any significant effect on the accumulation of RTV in MDCK-WT cells ( Figure 2C ).
The effect of Rh2 on RTV transport across MDCK-MDR1 monolayers was examined. In MDCK-MDR1 cells, the P app value of RTV in the BL-to-AP direction was markedly higher than that in the AP-to-BL direction, with an efflux ratio (BLto-AP/AP-to-BL) of approximately 45.92 ( Figure 2E ). In the presence of 1, 5, and 10 μmol/L Rh2, the efflux ratio of RTV decreased from 39.14 to 11.79 and finally 2.99. Ver (100 μmol/L) decreased the efflux ratio of RTV to approximately 2.99. However, in MDCK-WT cells, the permeability of RTV was comparable in both the absorptive (AP-BL) and secretory (BL-AP) directions, with efflux ratios (BL-to-AP/AP-to-BL) of approximately 0.86-1.12 ( Figure 2D ). The presence of Ver and Rh2 did not have any significant effect on RTV transport.
Differential effects of intragastrically and intravenously administered Rh2 on the pharmacokinetics of RTV
The intragastric administration of Rh2 did not have any significant effect on the pharmacokinetic profile or the parameters of RTV ( Figure 3 and Table 1 ). The increased dose of Rh2 had little effect on the pharmacokinetics of RTV. However, the pre-administration of Ver (20 mg/kg, po) or GF120918 (5 mg/kg, po) significantly increased the AUC of RTV by 3.60 The intravenous injection of Rh2 distinctly altered the pharmacokinetic profile and the RTV parameters. The pharmacokinetic profile of RTV was characterized by a delayed absorption phase and T max and an elevated C max (1.84-fold) and The terminal t 1/2 of RTV was increased after the intravenous injection of Rh2 (1.40-fold). However, there were no significant differences in the T max , C max , or AUC between the two groups treated with the intragastric and intravenous vehicles, indicating that the intravenous vehicle did not significantly affect the pharmacokinetic profile of RTV.
Differential effects of intragastrically and intravenously administered Rh2 on the concentration of RTV in the hepatic portal vein
The hepatic portal vein is a blood vessel that conducts blood from the gastrointestinal tract and spleen to the liver. This vein contains the drugs and metabolites absorbed from the gastrointestinal tract before reaching the systemic circulation. Quantitative measurement of the RTV concentration in the hepatic portal vein revealed that the intragastric administration of Rh2 or the established P-gp inhibitor GF120918
obviously increased the absorption of RTV, with increases from 301.4±77.9 h·ng/mL (AUC 0-8 h ) to 1234.8±277.3 h·ng/mL (P<0.05) and 3565.2±683.0 h·ng/mL (P<0.01), equivalent to 4.1-and 11.8-fold increases, respectively. The intravenous administration of Rh2 did not significantly affect the RTV profile in the hepatic portal vein, and the RTV profile under these conditions was similar to the profile associated with the blank vehicle ( Figure 4 ).
Differential effects of intragastrically and intravenously administered Rh2 on the excretion of RTV in bile, feces, and urine The level of RTV in the bile was profiled, and its kinetics in the presence of vehicle were compared with those in the presence of Rh2. It was shown that RTV was extensively metabolized in the liver, and the metabolite peaks were much larger, which agrees with the results of a previous study [20] (data not shown). The intravenous administration of Rh2 significantly decreased Table 1 . The effect of 20(S)-ginsenoside Rh2 and standard P-gp inhibitors on the pharmacokinetic parameters of ritonavir (RTV).
Regimen
Parameter (mean±SEM)
Vehicle A (po)+RTV 1.9±0. the cumulative excretion of RTV in bile from 0.69%±0.11% to 0.14%±0.03% (P<0.01), whereas the intragastric administration of Rh2 and GF120918 did not significantly affect the excretion of RTV, which is similar to the results obtained following the administration of the blank vehicle ( Figure 5A ). The measurement of the RTV level in feces indicated that 27.6%±3.3% of the dose was recovered in the feces in the original unchanged form of RTV after the intragastric administration of RTV. The oral administration of GF120918 significantly reduced the cumulative excretion of unchanged RTV in the feces to 18.5%±2.3% (P<0.05). The intragastric and intravenous administration of Rh2 did not significantly affect the excretion of RTV, similar to the administration of the blank vehicle. These results indicate that GF120918 greatly enhanced the gastrointestinal absorption of RTV by inhibiting P-gp.
The RTV concentration in the urine was also profiled and compared. The intragastric administration of Rh2 significantly promoted the cumulative excretion of RTV in the urine from 0.07%±0.02% to 0.29%±0.09% (P<0.05), whereas the administration of Rh2 (iv) and GF120918 (po) did not significantly affect the excretion of RTV, similar to the administration of the blank vehicle ( Figure 5C ).
Plasma pharmacokinetics of intragastrically and intravenously administered Rh2 in male Wistar rats
The concentration-time curve of Rh2 was also profiled in the same experiment used to evaluate the effect of Rh2 on the pharmacokinetics of RTV. Up to 19 h, the calculated AUC 0-19 h of orally administered Rh2 of 4.6±0.6 h·μg/mL was statistically equivalent to the value associated with intravenous administration (5.9±1.6 h·μg/mL). The absolute bioavailability was 15.4% ( Figure 6 ).
Intragastric administration of Rh2 increased the tissue/plasma ratio of RTV Compared with the vehicle control, pre-treatment with orally administered Rh2 had little effect on the plasma concentration of RTV but enhanced the movement of RTV from plasma into most tissues such as the liver, lungs, testes, fat, kidneys, and brain at 3 h and the lungs, kidneys, heart, small intestine, and spleen at 6 h, resulting in an elevated tissue/plasma ratio of RTV relative to that in the vehicle control group (Figure 7) . ing that RTV is a substrate of P-gp [9, 17] . In vitro experiments using MDCK-MDR1 and MDCK-WT cells indicated that Rh2 enhanced the accumulation of RTV in MDCK-MDR1 cells and exhibited a concentration-dependent effect on the inhibition of RTV efflux across MDCK-MDR1 monolayers in the same manner as the standard P-gp inhibitor Ver. However, the accumulation and efflux of RTV in MDCK-WT cells were only marginally affected. The differential effect of Rh2 on the accumulation and efflux of RTV in MDCK-MDR1 and MDCK-WT cells confirmed the inhibitory effect of Rh2 on P-gp [13] . Further experiments using the human intestinal epithelial cancer cell line Caco-2 revealed that Ver enhanced the accumulation and efflux inhibition of RTV, indicating that RTV is an effective substrate of intestinal P-gp. Rh2 enhanced the accumulation of RTV and had a concentration-dependent effect on the inhibition of RTV efflux across Caco-2 monolayers in the same manner as the standard P-gp inhibitor Ver. These data strongly suggest a potential pharmacokinetic interaction between RTV and Rh2 following oral administration.
The in vivo experiments demonstrated that the co-administration of oral Ver distinctly increased the bioavailability of RTV. Because Ver is an inhibitor of P-gp and CYP3A [21] , both of which may contribute to the increased bioavailability of RTV [9, 11] , another P-gp inhibitor, GF120918, which is not an inhibitor of CYP3A, was used in combination with RTV [22] . The co-administration with GF120918 significantly enhanced the RTV bioavailability, increased the level of RTV by 11.8-fold (AUC) in the hepatic portal vein and decreased the amount of RTV in feces, suggesting that the effect of GF120918 on P-gp inhibits the efflux of RTV in gastrointestinal cells and thus enhances the absorption of RTV. The above results confirm the effectiveness of P-gp inhibition on the enhancement of the gastrointestinal absorption of RTV.
Interestingly, despite the distinct inhibition by Rh2 of the P-gp-related accumulation and efflux of RTV in vitro, the intragastric administration of Rh2 at either 25 or 60 mg/kg had little effect on the bioavailability of RTV in rats. However, the intravenous injection of Rh2 at an amount equivalent to that administered intragastrically in terms of bioavailability (Figure 6 ) significantly increased the AUC and C max of RTV. RTV was administered 30 min after the intravenous injection of Rh2 and 60 min after the intragastric administration of Rh2 to give approximately the same plasma concentrations of Rh2. In contrast to our group's previous findings of increased exposure for P-gp substrates, digoxin, fexofenadine, and etoposide by concomitant intragastric administration of Rh2, RTV exposure failed to increase after the intragastric administration of Rh2 [13] . However, RTV exposure was increased after the concomitant intravenous administration of Rh2. The gradually ascending concentration of RTV and the obviously delayed T max (Figure 3 ) suggest that intravenous Rh2 had little effect on the early stage of RTV absorption in the gastrointestinal tract but instead primarily affected the profile of RTV at later stages. 
